Integral Diagnostics's FY 2026 Result Misses Consensus Hopes

Dow Jones

08/10

0000 GMT - Pathology services provider Integral Diagnostics's preliminary result for FY 2026 looks disappointing. Integral signaled annual revenue of A$788 million-A$790 million. That fell short of consensus hopes for A$799 million. Operating Ebitda of A$164 million-A$165 million missed market expectations for A$169 million. "While we had flagged downside risks to consensus numbers in our preview note, we expect the operating miss to be taken negatively by the market," says RBC Capital Markets. It had an outperform call and A$2.85/share price target on Integral entering this week. Integral ended Friday at A$2.18.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2658605135"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658605135\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658605135?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658605135","market":"us","top_or_hot":-1,"title":"Integral Diagnostics's FY 2026 Result Misses Consensus Hopes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0000 GMT - Pathology services provider <a href=\"https://laohu8.com/S/IDXN.AU\">Integral Diagnostics</a>'s preliminary result for FY 2026 looks disappointing. Integral signaled annual revenue of A$788 million-A$790 million. That fell short of consensus hopes for A$799 million. Operating Ebitda of A$164 million-A$165 million missed market expectations for A$169 million. \"While we had flagged downside risks to consensus numbers in our preview note, we expect the operating miss to be taken negatively by the market,\" says RBC Capital Markets. It had an outperform call and A$2.85/share price target on Integral entering this week. Integral ended Friday at A$2.18.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integral Diagnostics's FY 2026 Result Misses Consensus Hopes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntegral Diagnostics's FY 2026 Result Misses Consensus Hopes\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-08-10 08:00</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0000 GMT - Pathology services provider <a href=\"https://laohu8.com/S/IDXN.AU\">Integral Diagnostics</a>'s preliminary result for FY 2026 looks disappointing. Integral signaled annual revenue of A$788 million-A$790 million. That fell short of consensus hopes for A$799 million. Operating Ebitda of A$164 million-A$165 million missed market expectations for A$169 million. \"While we had flagged downside risks to consensus numbers in our preview note, we expect the operating miss to be taken negatively by the market,\" says RBC Capital Markets. It had an outperform call and A$2.85/share price target on Integral entering this week. Integral ended Friday at A$2.18.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INTEU","symbol_name":"Integral Acquisition Corporation 1","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2658605135","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658605135","pubTimestamp":1786320000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0000 GMT - Pathology services provider Integral Diagnostics's preliminary result for FY 2026 looks disappointing. Integral signaled annual revenue of A$788 million-A$790 million. That fell short of consensus hopes for A$799 million. Operating Ebitda of A$164 million-A$165 million missed market expectations for A$169 million. \"While we had flagged downside risks to consensus numbers in our preview note, we expect the operating miss to be taken negatively by the market,\" says RBC Capital Markets. It had an outperform call and A$2.85/share price target on Integral entering this week. Integral ended Friday at A$2.18.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INTEU":"Integral Acquisition Corporation 1","BK7124":"保健护理服务","IDX.AU":"INTEGRAL DIAGNOSTICS LTD"},"translate_title":"Integral Diagnostics 2026 财年业绩未达到共识预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTEU":1.5,"IDX.AU":0.9},"content_text":"0000 GMT - Pathology services provider Integral Diagnostics's preliminary result for FY 2026 looks disappointing. Integral signaled annual revenue of A$788 million-A$790 million. That fell short of consensus hopes for A$799 million. Operating Ebitda of A$164 million-A$165 million missed market expectations for A$169 million. \"While we had flagged downside risks to consensus numbers in our preview note, we expect the operating miss to be taken negatively by the market,\" says RBC Capital Markets. It had an outperform call and A$2.85/share price target on Integral entering this week. Integral ended Friday at A$2.18.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}